Many health technology assessment (HTA) agencies limit their assessment of vaccines to individual health benefits and the costs associated with vaccine administration and the disease avoided. However, compared to other health technologies, the standard evaluation approaches have often been criticised as inadequate to accurately estimate the value of vaccines.
This study uses a newly designed framework to capture the broader value of 10 selected vaccines with a high likelihood of entering the UK within the next decade. The findings qualify the critical gaps between value generation through vaccination and value recognition by relevant regulators. Recommendations are given to prevent the systematic undervaluation of future vaccines.